Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 90,300 shares, a drop of 33.9% from the November 30th total of 136,700 shares. Based on an average daily volume of 163,100 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Achilles Therapeutics

A hedge fund recently raised its stake in Achilles Therapeutics stock. XTX Topco Ltd lifted its stake in Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the quarter. XTX Topco Ltd owned 0.13% of Achilles Therapeutics worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 56.38% of the company’s stock.

Achilles Therapeutics Stock Performance

ACHL stock opened at $1.13 on Monday. The firm has a 50 day moving average price of $1.04 and a 200-day moving average price of $0.91. Achilles Therapeutics has a 52-week low of $0.63 and a 52-week high of $1.76. The firm has a market capitalization of $46.44 million, a price-to-earnings ratio of -0.68 and a beta of 1.37.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.